Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)

Completed

Conditions studied: Multiple Sclerosis

In brief

The aim of this retrospective study is to review and describe safety, tolerability and efficacy of Rebif® (subcutaneous interferon \[IFN\]-beta-1a) in children and adolescents, using information already recorded in medical records. The study duration is 13 July 2010 (first data collected) to 13 July 2011 (last data collected). In this study, Data of the subjects evaluated between 1997 and 2009 was observed.

Key facts

Study ID: NCT01207648
Run by: EMD Serono
People needed: 307
Starts: 2010-07-01
Expected to finish: 2011-07-01
Last updated by the study team: 2015-05-15

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Received one or more injections of Rebif® for treatment of a demyelinating event
Be younger than 18 years of age at time of Rebif® treatment initiation
Rebif® therapy must have been initiated before June 30, 2009

You may not qualify if…

No exclusion criteria are applied

Where it is running

Research Site — Birmingham, Alabama, United States
Research Site — San Francisco, California, United States
Research Site — Boston, Massachusetts, United States
Research Site — Buffalo, New York, United States
Research Site — Rochester, New York, United States
Research Site — Stoney Brook, New York, United States
Research Site — Buenos Aires, Argentina
Research Site — Toronto, Canada
Research Site — Le Kremlin-Bicêtre, France
Research Site — Bari, Italy
Research Site — Catania, Italy
Research Site — Gallarate, Italy
Research Site — Milan, Italy
Research Site — Rome, Italy
Research Site — Torino, Italy
Research Site — Moscow, Russia
Research Site — Tunis, Tunisia
Research Site — Maracaibo, Venezuela

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.